Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Multiple Oral Doses of HL237 in Healthy Males
NCT03896594Phase 1Unknown
- Sponsor
- Hanlim Pharm
- Start
- Dec 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HL237 in rheumatoid arthritis (RA) (4 arms), sponsored by Hanlim Pharm. Primary endpoints: Maximum Plasma Concentration at 14 days, Area Under the Curve at 14 days and 1 more. Status: unknown.
02
Drugs
HL237
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03896594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03896594.